Evidence-first guides
Longevity Treatments
Longevity treatments range from established medical procedures used for specific conditions to experimental interventions marketed ahead of the evidence. These guides compare what each treatment is, what human research supports, what it costs, which clinics report offering it, and which safety or regulatory questions to ask before paying.
NAD+ Therapy
Compare clinic availability, delivery methods, typical costs, and the limits of current human evidence for NAD+ protocols.
Read the evidence guide →Stem Cell Therapy
Understand cell sources, regulatory differences, clinic safeguards, pricing, and where regenerative claims exceed clinical evidence.
Read the evidence guide →Peptide Therapy
Review common peptide categories, medical supervision, regulatory status, costs, and the uneven evidence behind longevity claims.
Read the evidence guide →Plasmapheresis
Explore therapeutic plasma exchange, proposed longevity mechanisms, procedure costs, safety questions, and available clinics.
Read the evidence guide →Rapamycin Therapy
Assess rapamycin and mTOR inhibition, off-label prescribing, monitoring, human evidence limits, and ongoing healthy-aging trials.
Read the evidence guide →Senolytics
Follow the experimental effort to clear senescent cells, including evidence gaps, drug risks, and the current lack of matched providers.
Read the evidence guide →How to evaluate a treatment
A treatment belongs in a longevity plan only when the goal, evidence level, medical indication, product source, monitoring plan, adverse effects, and stop rules are explicit. A clinic offering a fashionable intervention is not evidence that the intervention improves lifespan or healthspan.